Alectinib
Brand names: Alecensa · Active ingredient: Alectinib Hydrochloride
In short: ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test . ALECENSA is indicated for the treatment of adult patients wi
What is Alectinib used for?
ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test .
ALECENSA is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test .
Alectinib dosage
Select patients with resectable tumors for the adjuvant treatment of NSCLC with ALECENSA based on the presence of ALK positivity in tumor tissue .
Select patients for the treatment of metastatic NSCLC with ALECENSA based on the presence of ALK positivity in tumor tissue or plasma specimens . If ALK rearrangements are not detected in a plasma specimen, test tumor tissue if feasible.
Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.
The recommended dosage information for ALECENSA is provided in Table 1.
Indication | Recommended Dosage of ALECENSA | Duration
Adjuvant treatment of resected NSCLC | 600 mg orally twice daily with food
| For a total of 2 years or until disease recurrence or unacceptable toxicity
Metastatic NSCLC | Until disease progression or unacceptable toxicity
Swallow capsules whole, do not open or dissolve the contents of the capsule.
If a dose of ALECENSA is missed or vomiting occurs after taking a dose of ALECENSA, take the next dose at the scheduled time.
The recommended dose of ALECENSA in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily .
The dose reduction schedule for ALECENSA is provided in Table 2.
Dose Reduction Schedule | Dose Level
Starting dose | 600 mg taken orally twice daily
First dose reduction | 450 mg taken orally twice daily
Second dose reduction | 300 mg taken orally twice daily
Discontinue if patients are unable to tolerate the 300 mg twice daily dose.
Recommendations for dose modifications of ALECENSA in case of adverse reactions are provided in Table 3.
CriteriaALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal; ILD = interstitial lung disease; CPK = blood creatine phosphokinase | ALECENSA Dose Modification
ALT or AST elevation of greater than 5 times upper limit of normal (ULN) with total bilirubin less than or equal to 2 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 3 times ULN, then resume at reduced dose as per Table 2.
ALT or AST elevation greater than 3 times ULN with total bilirubin elevation greater than 2 times ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA.
Total bilirubin elevation of greater than 3 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 1.5 times ULN, then resume at reduced dose as per Table 2.
Any grade treatment-related interstitial lung disease (ILD)/pneumonitis | Permanently discontinue ALECENSA.
Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to less than or equal to 1.5 times ULN, then resume at reduced dose.
Grade 4 renal impairment | Permanently discontinue ALECENSA. …
How to take Alectinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform patients of the following:
Hepatotoxicity
Inform patients of the signs and symptoms of bilirubin and hepatic transaminase elevations. Advise patients to contact their healthcare provider immediately for signs or symptoms of bilirubin and hepatic transaminase elevations .
Interstitial Lung Disease (ILD)/Pneumonitis
Inform patients of the risks of severe ILD/pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms .
Renal Impairment
Inform patients of the risk of severe and potentially fatal renal impairment. Advise patients to contact their healthcare provider immediately for change in urine color, reduced urine output, or new or worsening swelling in the legs and feet .
Bradycardia
Inform patients that symptoms of bradycardia including dizziness, lightheadedness, and syncope can occur while taking ALECENSA. Advise patients to contact their healthcare provider immediately to report these symptoms and to inform their healthcare provider about the use of any heart or blood pressure medications . …
Warnings & precautions
Do not take this medicine if: None.
Severe hepatotoxicity, including drug-induced liver injury, occurred in patients treated with ALECENSA.
In the pooled safety population of patients who received ALECENSA, hepatotoxicity occurred in 41% of patients and the incidence of Grade ≥ 3 hepatotoxicity was 8%. In the ALINA study, hepatotoxicity occurred in 61% of patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 4.7%. The majority (72% of 136 patients) of elevated transaminases occurred during the first 3 months of treatment. Treatment discontinuation due to hepatotoxicity occurred in 3.6% of patients who received ALECENSA in the pooled safety population and 1.6% of patients treated in the ALINA study.
In the pooled safety population, concurrent elevations in ALT or AST greater than or equal to 3 times the ULN and total bilirubin greater than or equal to 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients treated with ALECENSA. Three patients with Grades 3–4 AST/ALT elevations had drug-induced liver injury (documented by liver biopsy in two cases).
Monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse drug reaction, withhold ALECENSA and resume at a reduced dose or permanently discontinue ALECENSA as described in Table 3
.
ILD/pneumonitis occurred in patients treated with ALECENSA.
In the pooled safety population , ILD/pneumonitis occurred in 1.3% of patients treated with ALECENSA with 0.4% of patients experiencing Grade 3 ILD/pneumonitis.
Five patients (0.9%) in the pooled safety population discontinued ALECENSA due to ILD/pneumonitis. …
Alectinib side effects
The following adverse reactions are discussed in greater detail in other sections of the label:
Hepatotoxicity
Interstitial Lung Disease (ILD)/Pneumonitis
Renal Impairment
Bradycardia
Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
Hemolytic Anemia
Hypertriglyceridemia Leading to Pancreatitis
Embryo-Fetal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ALECENSA as a single agent at 600 mg orally twice daily in 533 patients in Studies NP28761, NP28673, ALEX and ALINA . Among 533 patients who received ALECENSA, 75% were exposed for 6 months or longer and 64% were exposed for greater than one year. In this pooled safety population, the most common (≥ 20%) adverse reactions were hepatotoxicity (41%), constipation (39%), fatigue (36%), myalgia (31%), edema (29%), rash (23%) and cough (21%). The most common (≥ 2%) Grade 3 or 4 laboratory abnormalities were increased CPK (6%), decreased hemoglobin (4.4%), increased ALT (4.2%), increased bilirubin (4.0%) and increased AST (3.4%). …
About this medicine
ALECENSA (alectinib) is a kinase inhibitor for oral administration. The molecular formula for alectinib is C30H34N4O2 ∙ HCl. The molecular weight is 482.62 g/mol (free base form) and 519.08 g/mol (hydrochloride salt). Alectinib is described chemically as 9-ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride. The chemical structure of alectinib is shown below:
Alectinib HCl is a white to yellow white powder or powder with lumps with a pKa of 7.05 (base).
ALECENSA is supplied as hard capsules containing 150 mg of alectinib (equivalent to 161.33 mg alectinib HCl) and the following inactive ingredients: carboxymethylcellulose calcium, hydroxypropylcellulose, lactose monohydrate, magnesium stearate and sodium lauryl sulfate. The capsule shell contains carnauba wax, carrageenan, corn starch, hypromellose, potassium chloride and titanium dioxide (E171). The printing ink contains carnauba wax, FD&C Blue No. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 42c49deb-713b-427a-9670-08af08adcffb. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate